INTELLIA THERAPEUTICS, INC. Operating Cash Flow
INTELLIA THERAPEUTICS, INC. (NTLA) reported Operating Cash Flow of -$200.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$83.11M.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$117.35M.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$69.28M.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$76.90M.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$394.74M.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$348.88M.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$394.09M.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$333.29M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$83.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$200.46M 10-Q · filed 2026-08-06 | -$269.74M derived: sum of 3 quarters · filed 2026-08-06 | -$346.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$117.35M 10-Q · filed 2026-05-11 | -$186.63M derived: sum of 2 quarters · filed 2026-05-11 | -$263.53M derived: sum of 3 quarters · filed 2026-05-11 | -$363.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$69.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$146.18M derived: sum of 2 quarters · filed 2026-02-26 | -$245.81M derived: sum of 3 quarters · filed 2026-08-06 | -$394.74M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$76.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$176.52M derived: sum of 2 quarters · filed 2026-08-06 | -$325.45M 10-Q · filed 2025-11-06 | -$410.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$99.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$248.55M 10-Q · filed 2026-08-06 | -$333.75M derived: sum of 3 quarters · filed 2026-08-06 | -$418.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$148.93M 10-Q · filed 2026-05-11 | -$234.13M derived: sum of 2 quarters · filed 2026-05-11 | -$318.96M derived: sum of 3 quarters · filed 2026-05-11 | -$377.15M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$85.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$170.03M derived: sum of 2 quarters · filed 2026-02-26 | -$228.22M derived: sum of 3 quarters · filed 2026-02-26 | -$348.88M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$84.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$143.02M derived: sum of 2 quarters · filed 2025-11-06 | -$263.69M 10-Q · filed 2025-11-06 | -$356.74M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$58.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$178.85M 10-Q · filed 2025-08-07 | -$271.90M derived: sum of 3 quarters · filed 2026-02-26 | -$373.28M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$120.66M 10-Q · filed 2025-05-08 | -$213.72M derived: sum of 2 quarters · filed 2026-02-26 | -$315.10M derived: sum of 3 quarters · filed 2026-02-26 | -$405.42M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$93.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$194.44M derived: sum of 2 quarters · filed 2026-02-26 | -$284.76M derived: sum of 3 quarters · filed 2026-02-26 | -$394.09M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$101.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$191.70M derived: sum of 2 quarters · filed 2024-11-07 | -$301.03M 10-Q · filed 2024-11-07 | -$390.90M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$90.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$199.65M 10-Q · filed 2024-08-08 | -$289.52M derived: sum of 3 quarters · filed 2025-02-27 | -$368.05M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$109.33M 10-Q · filed 2024-05-09 | -$199.20M derived: sum of 2 quarters · filed 2025-02-27 | -$277.72M derived: sum of 3 quarters · filed 2025-02-27 | -$362.81M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$89.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$168.40M derived: sum of 2 quarters · filed 2025-02-27 | -$253.49M derived: sum of 3 quarters · filed 2025-02-27 | -$333.29M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$78.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$163.62M derived: sum of 2 quarters · filed 2023-11-09 | -$243.42M 10-Q · filed 2023-11-09 | -$298.07M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$85.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$164.89M 10-Q · filed 2023-08-03 | -$219.54M derived: sum of 3 quarters · filed 2024-02-22 | -$284.56M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$79.80M 10-Q · filed 2023-05-04 | -$134.45M derived: sum of 2 quarters · filed 2024-02-22 | -$199.47M derived: sum of 3 quarters · filed 2024-02-22 | -$252.46M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$54.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$119.67M derived: sum of 2 quarters · filed 2024-02-22 | -$172.65M derived: sum of 3 quarters · filed 2024-02-22 | -$225.03M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$65.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$118.00M derived: sum of 2 quarters · filed 2022-11-03 | -$170.38M 10-Q · filed 2022-11-03 | -$210.60M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$52.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$105.36M 10-Q · filed 2022-08-04 | -$145.58M derived: sum of 3 quarters · filed 2023-02-23 | -$174.14M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$52.38M 10-Q · filed 2022-05-05 | -$92.60M derived: sum of 2 quarters · filed 2023-02-23 | -$121.16M derived: sum of 3 quarters · filed 2023-02-23 | -$63.74M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$40.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$68.78M derived: sum of 2 quarters · filed 2023-02-23 | -$11.37M derived: sum of 3 quarters · filed 2023-02-23 | -$49.91M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$28.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $28.86M derived: sum of 2 quarters · filed 2021-11-04 | -$9.69M 10-Q · filed 2021-11-04 | -$38.35M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $57.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $18.87M 10-Q · filed 2021-08-05 | -$9.79M derived: sum of 3 quarters · filed 2022-02-24 | -$35.24M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$38.55M 10-Q · filed 2021-05-06 | -$67.21M derived: sum of 2 quarters · filed 2022-02-24 | -$92.66M derived: sum of 3 quarters · filed 2022-02-24 | -$120.33M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$28.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$54.11M derived: sum of 2 quarters · filed 2022-02-24 | -$81.79M derived: sum of 3 quarters · filed 2022-02-24 | -$103.24M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$25.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$53.13M derived: sum of 2 quarters · filed 2020-11-05 | -$74.58M 10-Q · filed 2020-11-05 | -$83.12M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$27.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$49.13M 10-Q · filed 2020-08-06 | -$57.67M derived: sum of 3 quarters · filed 2021-02-26 | -$70.12M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$21.45M 10-Q · filed 2020-05-07 | -$29.99M derived: sum of 2 quarters · filed 2021-02-26 | -$42.45M derived: sum of 3 quarters · filed 2021-02-26 | -$64.94M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | -$8.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$20.99M derived: sum of 2 quarters · filed 2021-02-26 | -$43.49M derived: sum of 3 quarters · filed 2021-02-26 | -$61.26M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$12.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | -$34.95M derived: sum of 2 quarters · filed 2019-10-31 | -$52.72M 10-Q · filed 2019-10-31 | -$74.03M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$22.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$40.27M 10-Q · filed 2019-08-01 | -$61.57M derived: sum of 3 quarters · filed 2020-02-27 | -$78.47M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$17.77M 10-Q · filed 2019-05-02 | -$39.08M derived: sum of 2 quarters · filed 2020-02-27 | -$55.97M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2017-12-31 | -$21.31M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$38.20M derived: sum of 2 quarters · filed 2020-02-27 | -$65.28M 10-K · filed 2020-02-27 | |
| 2017-09-30 | -$16.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | -$43.97M 10-Q · filed 2018-10-31 | ||
| 2017-06-30 | -$27.08M 10-Q · filed 2018-08-01 | |||
| 2016-12-31 | $36.11M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |